Mechanism of Action & Delivery

CAYSTON is the only FDA-approved MONOBACTAM inhaled antibiotic to treat cystic fibrosis (CF) patients with PSEUDOMONAS AERUGINOSA (Pa)

Activity in vitro against Pa, a Gram-negative bacteria

  • The chemical structure confers specificity for aerobic Gram-negative bacteria and enhances beta-lactamase stability
  • Binds to penicillin-binding proteins of susceptible bacteria
  • Leads to inhibition of bacterial cell wall synthesis and death of the cell
  • Activity not decreased in the presence of CF lung secretions

Cell wall maintenance of Pa

Inhibition of Pa cell wall synthesis icon

Pa cell wall layer

Connections between cell wall layers are made by penicillin-binding proteins, providing structural integrity

Penicillin-binding protein

CAYSTON binds to penicillin-binding protein of Pa

CAYSTON binds to penicillin-binding protein of Pa icon

CAYSTON

Inhibition of Pa cell wall synthesis and cell death

Cell wall maintenance of Pa icon

Delivery

Inhaled antibiotic delivered directly to the airways

  • The airways of the lungs are the site of Pa infection
  • CAYSTON is aztreonam that has been reformulated for inhalation with the amino acid lysine

CF airway infected with Pa

Pseudomonas aeruginosa infected airway image
Emily, a real patient treated with CAYSTON

"I know now that it is very important to treat Pa. My doctor told me that, if left untreated, my breathing symptoms could get worse and I may see a further decline in my lung function."

Read how Emily, a real patient treated with CAYSTON, manages her Pa.

Learn About CAYSTON's Systemic Exposure & Microbiology
NEXT